2026/05/05 by David Weber, Joshua Modeste, Sarah Peeling +5 · 1 voice
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Diabetes Management and Research #Diabetes and associated disorders #T-cell and B-cell Immunology
paper · doi:10.2337/dc26-0223
openalex publication_date 2026/05/05 · openalex created_date 2026/05/06 · openalex updated_date 2026/08/01
OBJECTIVE: To evaluate the real-world feasibility and efficacy of low-dose antithymocyte globulin (ATG) by an exploratory modified quantitative response (mQR) of C-peptide in type 1 diabetes. RESEARCH DESIGN AND METHODS: Individuals with stage 2 (n = 6) or stage 3 (n = 33) diabetes were treated clinically with low-dose ATG (2.5 mg/kg) and asked to obtain C-peptide via a commercial laboratory 90 min postconsumption of 6 mL/kg Boost. Thirty individuals (77%) completed 1 year of follow-up, with 22 (73% of those) providing pre-ATG and 1-year-post-ATG C-peptides. Area under the curve C-peptide was estimated from 90-min values to calculate mQR. RESULTS: In the 22 evaluable patients, average mQR at 1 year was 0.072. Average HbA1c decreased from 7.1% (54 mmol/mol) to 6.0% (42 mmol/mol). There were 15 responders (+mQR) and 7 nonresponders (-mQR). There were no unexpected side effects. CONCLUSIONS: C-peptide mQR was feasible and produced expected responder frequencies following low-dose ATG in a clinical practice setting.